For Immediate Release

Chicago, IL – September 7 – Zacks highlights commentary from People and Picks Trader “BioMO”.

For more Voice of the People, visit

Featured Post

New Pick: Cadence Pharma

Candence Pharmaceuticals (CADX) has an early November PDUFA date and expected FDA decision for OFIRMEV (intravenous or IV acetaminophen).

CADX is developing OFIRMEV (acetaminophen) injection in the U.S. market for the treatment of acute pain.

CADX has in-licensed the exclusive U.S. and Canadian rights to OFIRMEV™, an intravenous formulation of acetaminophen that is currently marketed in Europe for the treatment of acute pain and fever by Bristol-Myers Squibb Company, or BMS, under the brand name Perfalgan®. According to IMS data, since its introduction beginning in 2002, over 250 million doses of intravenous acetaminophen have been sold in Europe and it has become the market share leader among injectable analgesics.

Because of delays we can look back at two recent run-ups of CADX.

During its run-up in 2009 CADX hit a high of $11.76 (10/12/09) During its Feb 2010 run-up CADX hit a high of $10.91 (1/7/10)

The stock price as this is written is 7.99.

Our target price, assuming it is dilution-free, is $10.50. This would be a 30% gain.

We are targeting this price prior to the FDA approval date in November 13

Another way to play this stock is via options. $10 November Calls which expire AFTER the FDA date of 11/4/10, allows for speculation on share price if approved. Currently these calls are trading for around $.90, expectations is that the calls should be “in the money” before 11/4/10.

CADX as to the ‘game’ is being added as an stock pick. Disclosure: I am an alter-ego of MightyMo. ALIGN=”left”> To learn more about People And Picks, visit

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3:1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it’s your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit From the Pros by going to

Follow us on Twitter:

Join us on Facebook:

Visit for information about the performance numbers displayed in this press release.

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact: Brent Billock
People & Picks Manager
Phone: 312-265-9307


CADENCE PHARMA (CADX): Free Stock Analysis Report
Zacks Investment Research